Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Robert R. McWilliams, MD
Hoosier Cancer Research Network
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic- Florida
Jacksonville, Florida, United States
- University of Iowa Hospital and Clinics
Iowa City, Iowa, United States
- University of Minnesota
Minneapolis, Minnesota, United States
- Mayo Clinic Rochester
Rochester, Minnesota, United States
- Nebraska Cancer Specialists
Omaha, Nebraska, United States
- Providence Portland Medical Center
Portland, Oregon, United States
- Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 12 Sept 2017
- Primary completion
- 15 Sept 2022
- Completion
- 30 Sept 2023
- Last update posted
- 9 Dec 2022
- Registered enrollment
- 36
- Registry id
- NCT03241186
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.